Corticosteroids in idiopathic pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 7, Issue 5, 2001, Pages 298-308

  Lynch III, Joseph P ^a,b   White, Eric ^a   Flaherty, Kevin ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; PREDNISOLONE;

CATARACT; CLINICAL FEATURE; DEMOGRAPHY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; HUMAN; HYPERGLYCEMIA; LUNG FIBROSIS; METABOLIC ALKALOSIS; OPEN LUNG BIOPSY; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATHOGENESIS; PEPTIC ULCER; PROGNOSIS; PSYCHOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SURVIVAL RATE; VALIDATION PROCESS;

EID: 0034815357     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200109000-00009     Document Type: Review

References (121)

1. Prognosis of cryptogenic fibrosing alveolitis
2. Cryptogenic fibrosing alveolitis: Response to corticosteroid treatment and its effect on survival
3. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International Consensus Statement
4. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival
5. Survival in patients with cryptogenic fibrosing alveolitis. A population-based cohort study
6. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF
7. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future
8. Steroids in idiopathic pulmonary fibrosis: A prospective assessment of adverse reactions, response to therapy, and survival
9. Idiopathic pulmonary fibrosis: Current concepts
10. Standards of Care Committee. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults
11. The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom
12. British Thoracic Society study of cryptogenic fibrosing alveolitis: Current presentation and initial management
13. Idiopathic pulmonary fibrosis
14. Prognostic significance of histopathological subsets in idiopathic pulmonary fibrosis
15. Idiopathic nonspecific interstitial pneumonia/fibrosis: Comparison with idiopathic pulmonary fibrosis and BOOP
16. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome?
17. Idiopathic nonspecific interstitial pneumonia: Prognostic significance of cellular and fibrosing patterns: Survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia
18. Mortality rates from cryptogenic fibrosing alveolitis in seven countries
19. The epidemiology of interstitial lung diseases
20. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebo-controlled clinical trial
21. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis
22. Idiopathic pulmonary fibrosis. Pretreatment bronchoalveolar lavage cellular constituents and their relationships with lung histopathology and clinical response to therapy
23. Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine
24. Natural history and treated course of usual and desquamative interstitial pneumonia
25. Idiopathic pulmonary fibrosis: Clinical relevance of pathologic classification
26. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance
27. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis
28. Acute interstitial pneumonitis. Case series and review of the literature
29. Acute interstitial pneumonia
30. Reactive pulmonary lymphoid disorders
31. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients
32. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis
33. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis
34. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis
35. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis
36. Clinical significance of histopathologic classification of idiopathic interstitial pneumonia
37. High short-term mortality following lung biopsy for usual interstitial pneumonia
38. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings
39. Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis
40. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study
41. Idiopathic interstitial pneumonias: Diagnostic accuracy of thin-section CT in 129 patients
42. Accuracy of the typical computed tomographic appearances of fibrosing alveolitis
43. Diffuse lung disease: Diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung
44. Bronchoalveolar lavage cellularity. Lone cryptogenic fibrosing alveolitis compared with the fibrosing alveolitis of systemic sclerosis
45. Usual interstitial pneumonia: Histologic correlation with high-resolution CT
46. Desquamative interstitial pneumonia: Thin section CT findings in 22 patients
47. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
48. Importance of ground glass attenuation in chronic diffuse infiltrative lung disease: Pathologic CT correlation
49. Idiopathic pulmonary fibrosis. Predicting response to therapy and survival
50. Fibrosing alveolitis: Prognostic implication of ground glass attenuation at high-resolution CT
51. Functional impairment in fibrosing alveolitis: Relationship to reversible disease on thin section computed tomography
52. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: Correlation with pathologic scoring
53. Idiopathic pulmonary fibrosis: Progression of honeycombing at thin-section CT
54. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT
55. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis
56. Serial CT in fibrosing alveolitis: Prognostic significance of the initial pattern
57. Fibrosing alveolitis: Chest radiography and CT as predictors of clinical and functional impairment at follow-up in 26 patients
58. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy
59. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects
60. Circulating immune complexes in the idiopathic interstitial pneumonias
61. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders: State of the art
62. Idiopathic pulmonary fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy
63. Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias
64. Significance of early intraalveolar fibrotic lesions and integrin expression in lung biopsy specimens from patients with idiopathic pulmonary fibrosis
65. Tenascin mRNA expression at the foci of recent injury in usual interstitial pneumonia
66. Pathogenesis of idiopathic interstitial pulmonary fibrosis
67. Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung
68. Triggering the induction of myofibroblast and fibrogenesis by airway epithelial shedding
69. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinase expression
70. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis
71. Alveolar macrophages release an insulin-like growth factor I-type molecule
72. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators
73. Increased number of alveolar macrophages expressing surface molecules of the CD11/CD18 family in sarcoidosis and idiopathic pulmonary fibrosis is related to the production of superoxide anions by these cells
74. Tenascin immunereactivity as a prognostic marker in usual interstitial pneumonia
75. Type III and type I procollagen markers in fibrosing alveolitis
76. Fibronectin in human brenchepulmonary lavage fluid: Elevation in patients with interstitial lung disease
77. Production of fibronectin by the human alveolar macrophage: Mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung diseases
78. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis
79. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis
80. Adhesion molecule expression in the lung: A comparison between normal and diffuse interstitial lung disease
81. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent
82. Increased oxidation of extracellular glutathiene by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitis
83. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis
84. Determinants of response to immunesuppressive therapy in idiopathic pulmonary fibrosis
85. Cyclophesphamide in the treatment of idiopathic pulmonary fibrosis
86. Colchicine versus prednisone as treatment of usual interstitial pneumonitis
87. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis. A controlled clinical trial
88. Approaches to the treatment of pulmonary fibrosis
89. Pharmacological therapy for idiopathic pulmonary fibrosis
90. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis
91. Histopathological variability in idiopathic interstitial pneumonia: Clinical implications
92. Clinical significance of respiratory bronchiolitis on open lung biopsy and its relationship to smoking related interstitial lung disease
93. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic non-specific interstitial pneumonia
94. Non-specific interstitial pneumonia: Findings on sequential CT scans of nine patients
95. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease
96. Side-effects of corticosteroid agents
97. A preliminary study of long-term treatment with interferon gamma-1 b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis
98. Osteoporosis prevention diagnosis therapy
99. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial (European Corticosteroid-Induced Osteoporosis Treatment Study)
100. Hip fractures attributable to corticosteroid use
101. Calcium and vitamin D for corticostoroid-induced osteoporosis (Cochrane Review)
102. Alendronate for the treatment of osteoporosis in men
103. Alendronate for the prevention and treatment of glucocorticoid-induced osteoperesis
104. Acute effects of etidronate on glucocorticoid-induced bone degradation
105. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion once every three months, and calcium alone
106. Association of adrenocorticosteroid therapy and peptic-ulcer disease
107. Corticosteroids and peptic ulcer: Meta-analysis of adverse events during steroid therapy
108. Idiopathic pulmonary fibrosis. A practical approach for diagnosis and management
109. Treatment of idiopathic pulmonary fibrosis: The rise and fall of corticosteroids
110. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis
111. The role of pulmonary function testing in pulmonary fibrosis
112. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis
113. Six-minute walk testing
114. The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study
115. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression
116. Captopril inhibits apoptosis in human lung epithelial cells: A potential antifibrotic mechanism
117. Perspectives and future advances on the diagnosis and treatment of idiopathic pulmonary fibrosis
118. Keratinocyte growth factor reduces lung damage due to acid instillation in rats
119. Keratinocyte growth factor ameliorates radiation- and bleomycin-induced lung injury and mortality
120. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo
121. Lovastatin induces fibroblast apoptosis in vitro and in vivo: A possible therapy for fibroproliferative disorders